Table 5. Comparative analysis of CAPOX vs. FOLFIRINOX.
| Characteristic | Overall | Significance | CAPOX (n=23) | FOLFIRINOX (n=47) | Significance (CAPOX vs. FOLFIRINOX) |
|---|---|---|---|---|---|
| TRG (n=45) | NS | 5 (21.7%) | 19 (59.3%) | NS | |
| TRG (1/5 and 2/5) | 53.5% | ||||
| TRG (3/5–5/5) | 46.5% | ||||
| Pathological CR (pCR) (n=45) | NS | NS | |||
| pCR | 20 (44.4%) | 3 | 5 | ||
| No pCR | 25 (55.6%) | 10 | 24 | ||
| Surgery | NA | NS | |||
| Conservative | 37 | 10 | 23 | ||
| TPE | 10 | 4 | 6 | ||
| Awaiting conservative surgery | 2 | 0 | 2 | ||
| Awaiting TPE | 1 | 0 | 1 | ||
| Refused surgery | 5 | 3 | 2 | ||
| Inoperable/unresectable | 20 | 7 | 11 | ||
| Response evaluation not done | 1 | 0 | 1 | ||
| EFS | |||||
| Median EFS (months) | 19.2 | NA | 16.9 | 19.2 | NS |
| 2-year EFS | 48% | – | – | – | – |
| 2-year OS | |||||
| Whole cohort | 56% | NA | 43.8% | 67.1% | NS |
| Outcomes in patients undergoing surgery (n=47) | 86% | NA | – | – | – |
| Outcomes in patients undergoing conservative surgery (n=37) | 84% | NA | 70% | 95.7% | 0.012 |
CAPOX, capecitabine plus oxaliplatin; FOLFIRINOX, 5-FU plus irinotecan plus oxaliplatin; TRG, tumor regression grade; NS, not significant; TPE, total pelvic exenteration; NA, not applicable; EFS, event free survival.